JYPC signed a technology development contract with Hunan University of Traditional Chinese Medicine

According to the Zhitong Finance APP, JYPC (002198.SZ) announced that recently, its wholly-owned subsidiary JYPC (Hunan) Co., Ltd. (hereinafter referred to as "the subsidiary" or "Party B") signed a "Technology Development Contract" with Hunan University of Traditional Chinese Medicine (hereinafter referred to as "Party A").

Involved technical content: Party A is responsible for providing suitable traditional Chinese medicine prescriptions and corresponding technical support (including but not limited to clinical positioning, clinical value and prescription characteristics, pharmaceutical process guidance based on clinical applications, clinical trial protocols, etc.); Party B will conduct pharmaceutical research, pharmacological and toxicological research, clinical research, and all new drug registration application requirements for the innovative traditional Chinese medicine Class 1.1 "Juanbi Lijie Qing Granules" in accordance with the current NMPA "Drug Registration Management Measures" (2020), "Traditional Chinese Medicine Registration Classification and Application Materials Requirements" (2020), "Special Regulations on Traditional Chinese Medicine Registration Management" (2023), "Guiding Principles for the Research of Production Processes of Traditional Chinese Medicine Compound Preparations (Trial)" and other relevant regulations, and carry out the new drug registration application for "Juanbi Lijie Qing Granules", ultimately developing an innovative drug with significant efficacy, clear mechanisms, and distinct traditional Chinese medicine characteristics—Juanbi Lijie Qing Granules, and obtaining the drug clinical trial approval notice